Myriad Genetics Inc
(MYGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -62,700 | -26,000 | -263,300 | -232,100 | -170,800 |
| Depreciation Amortization | 43,600 | 15,700 | 61,900 | 46,800 | 32,700 |
| Income taxes - deferred | -1,600 | N/A | -4,000 | -1,700 | -700 |
| Accounts receivable | -4,500 | -3,900 | -12,500 | -13,700 | -10,100 |
| Accounts payable and accrued liabilities | 9,400 | 6,100 | -3,700 | 2,200 | 10,700 |
| Other Working Capital | -22,900 | -20,600 | 10,700 | 68,300 | 58,500 |
| Other Operating Activity | 22,700 | 10,100 | 100,000 | 74,000 | 45,600 |
| Operating Cash Flow | $-16,000 | $-18,600 | $-110,900 | $-56,200 | $-34,100 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -11,900 | -6,700 | -63,200 | -53,200 | -42,300 |
| Sale Of Investment | 4,000 | 1,500 | 105,200 | 103,700 | 88,700 |
| Purchase Sale Intangibles | -5,600 | -1,900 | -10,100 | -6,600 | 0 |
| Other Investing Activity | -5,600 | -1,900 | -10,100 | -6,600 | 0 |
| Investing Cash Flow | $-13,500 | $-7,100 | $31,900 | $43,900 | $46,400 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 80,000 | 60,000 | 80,000 | 40,000 | 40,000 |
| Debt Repayment | -80,200 | -60,100 | -40,200 | -100 | 0 |
| Common Stock Issued | 3,000 | N/A | 123,600 | 0 | 0 |
| Other Financing Activity | -9,200 | -8,700 | -10,500 | -8,900 | -6,500 |
| Financing Cash Flow | $-6,400 | $-8,800 | $152,900 | $31,000 | $33,500 |
| Exchange Rate Effect | -1,500 | -800 | 600 | -100 | 500 |
| Beginning Cash Position | 140,900 | 140,900 | 66,400 | 66,400 | 66,400 |
| End Cash Position | 101,200 | 105,600 | 140,900 | 85,000 | 112,700 |
| Net Cash Flow | $-39,700 | $-35,300 | $74,500 | $18,600 | $46,300 |
| Free Cash Flow | |||||
| Operating Cash Flow | -16,000 | -18,600 | -110,900 | -56,200 | -34,100 |
| Capital Expenditure | -11,900 | -6,700 | -63,200 | -53,200 | -42,300 |
| Free Cash Flow | -27,900 | -25,300 | -174,100 | -109,400 | -76,400 |